Non-Executive Director Jin Hong-guk Exercises 20,000 Stock Options in AprilBio, Stake Rises to 0.13%, Limited Impact on Share Price

Non-executive director Jin Hong-guk of AprilBio exercised 20,000 stock options on April 13, 2026, increasing his holdings from 10,000 to 30,000 shares.
The exercise price of 10,875 KRW per share is significantly below the current market price of 60,700 KRW, generating a paper gain, but the new shares represent only 0.09% of total outstanding shares, resulting in negligible dilution for existing shareholders.
This exercise is part of executive compensation and does not involve corporate fundraising, with no material governance issues.
[AI Summary]Jin Hong-guk's stock option exercise slightly raised his stake to 0.13%, but with a dilution of just 0.09% of total shares, the impact on shareholder value is minimal. It is a routine compensation event with no strategic or fundraising implications, thus limited market shock.